Page last updated: 2024-12-06

eperezolid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID73214
CHEMBL ID47955
SCHEMBL ID186562
MeSH IDM0257533

Synonyms (38)

Synonym
acetamide, n-((3-(3-fluoro-4-(4-(hydroxyacetyl)-1-piperazynyl)phenyl)- 2-oxo-5-oxazolidinyl)methyl)-, (s)-
u-100592
eperezolid ,
165800-04-4
n-[[(5s)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
acetamide, n-((3-(3-fluoro-4-(4-(hydroxyacetyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (s)-
u 100592
n-(((s)-3-(3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
eperezolid [usan]
D04017
eperezolid (usan/inn)
CHEMBL47955
u-100,592
AKOS015951014
c460zsu1ow ,
unii-c460zsu1ow
eperezolid [usan:inn]
n-((3-(3-fluoro-4-(n-1-(4-hydroxyacetyl)piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
bdbm50433368
HY-10393
SCHEMBL186562
eperezolid [who-dd]
n-[[(s)-3-[3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
eperezolid [inn]
(s)-n-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
SIMWTRCFFSTNMG-AWEZNQCLSA-N
(s)-n-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1 -piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
(s)-n-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
DTXSID50168028
EX-A5272
NCGC00378601-01
(s)-n-((3-(3-fluoro-4-(4-(2-hydroxyacetyl)piperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
Q1346746
u100592
gtpl10803
comound 2 [pmid: 23584544]
MS-26621
pnu-100592pnu-100592

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The objective of this study was to evaluate a physiologically based pharmacokinetic (PBPK) approach for predicting the plasma concentration-time curves expected after intravenous administration of candidate drugs to rodents."( Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.
Burton, PS; Crivori, P; Germani, M; Poggesi, I; Rocchetti, M; Smith, ME; Wilson, AG, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
"The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity against antibiotic-susceptible and -resistant gram-positive pathogens."( In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.
Barbachyn, MR; Brickner, SJ; Ford, CW; Hamel, JC; Hutchinson, DK; Moerman, JK; Stapert, D; Wilson, DM; Yancey, RJ, 1996
)
0.29
" Linezolid, the oxazolidinone which has been selected for clinical development, has near complete oral bioavailability plus favourable pharmacokinetic and toxicity profiles."( Oxazolidinones: a review.
Diekema, DI; Jones, RN, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" faecalis sera from patients dosed with either drug were generally inhibitory at the peak timepoint, but at trough only linezolid exhibited a persistent effect."( Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid.
Batts, DH; Daley-Yates, PT; Pawsey, SD; Schaadt, RD; Stalker, DJ; Zurenko, GE, 1997
)
0.5
" A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight)."( Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Chase, S; Cynamon, MH; Klemens, SP; Sharpe, CA, 1999
)
0.3
" At a dosage of 100 mg/kg/day, linezolid treatment led to an approximately 100-fold reduction in viable cells per gram of abscess."( Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
Eliopoulos, GM; Moellering, RC; Schülin, T; Thauvin-Eliopoulos, C, 1999
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)20.00000.00011.774010.0000AID745377
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)20.00000.00011.753610.0000AID745375
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)20.00000.00002.015110.0000AID745376
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)20.00000.00002.800510.0000AID745378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (217)

Assay IDTitleYearJournalArticle
AID745401Antibacterial activity against Streptococcus pneumoniae SR26207 clinical isolate assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID209934Inhibitory activity against Streptococcus pyogenes1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID208011The compound was evaluated for its anti-bacterial activity against Streptococcus pneumoniae UC 99121998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID206787Inhibitory activity against MSSA1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID383564Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206088In vitro anti-streptococcal activity against Streptococci species (viridans) [25]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID125242The compound was evaluated for its anti-bacterial activity against Moraxella catarrhalis UC 306101998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID65385Inhibitory activity against Enterococcus faecalis UC92172000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID383565Antibacterial activity against Staphylococcus aureus ATCC 9144 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID125104Inhibitory activity against Moraxella catarrhalis1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID1369124Antibacterial activity against Acinetobacter baumannii ATCC 17978 after 18 hrs by broth microdilution method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic.
AID745400Antibacterial activity against Haemophilus influenzae SR27914 clinical isolate assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID319146Solubility in phosphate buffer at pH 72008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID67579Minimum inhibitory concentration against Enterococcus faecalis UC92171998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID244815Minimum inhibitory concentration against Staphylococcus aureus A150902005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID50998In vitro antibacterial activity against Clostridium perfringens strain ATCC 131241996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID134123Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus aureus HT18) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID133300Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus aureus HT-18 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID201444Inhibitory activity against Methicillin-resistant Staphylococcus epidermidis UC120842000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID207511Minimum inhibitory concentration against Staphylococcus aureus UC92131998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID262232Antibacterial activity against Staphylococcus aureus ATCC 292132006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID383556Antibacterial activity against Bacillus cereus ATCC 11778 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID745402Antibacterial activity against Moraxella catarrhalis SR26840 clinical isolate assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID197767Compound was evaluated for metabolic stability via In vitro Rat 5E6 cell at 50 uM concentration2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID205680Minimum inhibitory concentration against Staphylococcus aureus MTCC 96; Not determined2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID1553369Inhibition of protein synthesis in mitochondria (unknown origin) assessed as [35S]methionine incorporation incubated for 15 to 120 mins by paper disk assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity.
AID308916Antibacterial activity against Staphylococcus aureus ATCC 33591 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID134119Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus agalactiae B1HT3 strain) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID745382Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 infected in JCL/ICR mouse systemic infection model assessed as mortality administered as iv measured over 7 days2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID201408Inhibitory activity against Methicillin-resistant Staphylococcus aureus UC66852000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID383566Antibacterial activity against Staphylococcus aureus ATCC 14154 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206127In vitro antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus (CRSA) C6043.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID226024Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3AP9 strain ) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID112683In vivo antibacterial activity against Enterococcus faecium strain UC 15090 administered perorally in mice1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID206090Minimum inhibitory concentration evaluated against Streptococci species (viridans) [25]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID223270Dose required to cure 50% of Staphylococcus aureus infected mice in the presence of vancomycin when administered orally; value ranges from 2.5-6.42000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID745383Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID128015Compound was tested against Staphylococcus aureus UC9213 after po administration in mouse1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID262231Antibacterial activity against Staphylococcus aureus ATCC 141542006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID27799Volume distribution in Male Sprague-Dawley Rat (25 mg/kg po); NC denotes not calculated2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID266689Antibacterial activity against Staphylococcus aureus ATCC 259232006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: a novel class of antibacterial agents.
AID383569Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 120 with G 2576T mutation by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206841Minimum inhibitory concentration evaluated against Staphylococcus species resistant to oxacillin and ofloxacin [47]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID94375In vitro antibacterial activity against Klebsiella pneumoniae strain UC 120811996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID29427Oral bioavailability in rat (Sprague-Dawley) (male) (dose 10 mg/kg i.v.)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID308921Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206786Inhibitory activity against MRSA1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID223279Dose required to cure 50% of Staphylococcus aureus infected mice when administered orally; value ranges from 1.4-3.82000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID66098Inhibitory activity against Enterococcus faecium1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID67894The compound was evaluated for its anti-bacterial activity against Enterococcus faecalis UC 92171998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID133297Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus aureus GR56 strain resistant to oxacillin in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID79584Inhibitory activity against Haemophilus influenzae UC300632000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID245167Minimum inhibitory concentration against homogeneously methicillin-resistant Staphylococcus aureus A272232005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID40483Minimum inhibitory concentration against Bacillus pumilus MTCC 16072004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID206281In vitro antibacterial activity against Staphylococcus aureus (S. a.) ATCC 29213.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID66561Minimum inhibitory concentration evaluated against enterococci species susceptible to vancomycin [26]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID226027Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3HT12 strain ) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID245196Minimum inhibitory concentration against heterogeneously methicillin-resistant Staphylococcus aureus A272182005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID91253Compound was evaluated for metabolic stability via In vitro Human 5E6 cell at 25 uM concentration; ND denotes not determined2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID206089In vitro anti-streptococcal activity against Streptococci species [38]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID209767Minimum inhibitory concentration against Streptococcus pyogenes MTCC 4422004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID206727In vitro antibacterial activity against the methicillin-resistant Staphylococcus aureus 881999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.
AID68242In vitro antibacterial activity against Enterococcus faecium C6301 (E.f.2).1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID262228Antibacterial activity against Enterococcus faecalis ATCC 355502006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID133419Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3HM4 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID205897Minimum inhibitory concentration against Staphylococcus epidermidis MTCC 1552004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID68385In vitro antibacterial activity against Enterococcus faecium strain UC127121996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID244814Minimum inhibitory concentration against Enterococcus faecalis A206882005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID206234Minimum inhibitory concentration against Staphylococcus epidermis UC120841998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID308915Antibacterial activity against Enterococcus faecalis ATCC 14506 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID28208Tmax value in Male Sprague-Dawley Rat at dose 10 (mg/kg iv) [tmax (h)]; ND denotes not reported2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID134121Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus aureus GR56 strain resistant to oxacillin) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID319151Toxicity in rat at 25 mg/kg for 30 days2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID93890Minimum inhibitory concentration against Klebsiella pneumoniae ATCC 100312004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID383561Antibacterial activity against Enterococcus faecalis ATCC 14506 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID383563Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID226022Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Enterococci faecium D3HT7 strain ) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID209475In vitro antibacterial activity against Streptococcus pyogenes strain UC 1521996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID206839Minimum inhibitory concentration evaluated against Staphylococcus species resistant to ofloxacin [59]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1369125Antibacterial activity against Acinetobacter baumannii ATCC 17978 transfected with pNT255 after 18 hrs by broth microdilution method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic.
AID383567Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID226021Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Enterococci faecalis D2HT6 strain) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308922Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID83650Inhibitory activity against Haemophilus influenzae1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID66405In vitro anti-enterococcal activity against enterococci species resistant to vancomycin [65]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID319152Toxicity in dog at 25 mg/kg for 30 days2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID112686In vivo antibacterial activity against Staphylococcus aures strain UC 9213 administered subcutaneously in mice1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID68244In vitro antibacterial activity against vancomycin-resistant Enterococcus faecium C6487 (VRE).1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID1471363Inhibition of coupled transcription-translation in Escherichia coli UC6782 30S ribosome subunit using ortho-nitrophenyl-beta-galactoside as substrate after 30 mins by spectrophotometry2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.
AID308914Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206833In vitro anti-staphylococcal activity against Staphylococcus species resistant to oxacillin [66]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308913Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID133294Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus agalactiae B1HT3 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206228In vitro antibacterial activity against Staphylococcus epidermis strain UC 300311996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID206236In vitro antibacterial activity against Staphylococcus aures strain ATCC 292131996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745403Antibacterial activity against Enterococcus faecium SR7940 clinical isolate assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID210379In vitro antibacterial activity against Streptococcus pneumoniae strain UC 99121996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745405Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS271 assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID745374Inhibition of MAO-A in rat forebrain using [14C]5-HT as substrate at 30 uM incubated for 20 mins prior to substrate addition measured after 5 mins by liquid scintillation counting analysis relative to control2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID28087Cmax value in Male Sprague-Dawley Rat at dose 25 (mg/kg po)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID383558Antibacterial activity against Staphylococcus epidermidis ATCC 155 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID28199Plasma clearance in Male Sprague-Dawley Rat (25 mg/kg po); ND denotes not reported2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID262234Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 1192006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID206237In vitro antibacterial activity against Staphylococcus aures strain UC 92131996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID145139In vitro antibacterial activity against Mycobacterium tuberculosis strain H37Rv1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745406Antibacterial activity against Staphylococcus aureus Smith assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID262226Antibacterial activity against Bacillus pumilus ATCC 143482006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID112685In vivo antibacterial activity against Staphylococcus aures strain UC 9213 administered perorally in mice1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID1369126Antibacterial activity against Acinetobacter baumannii ATCC 17978 transfected with pNT255:ADC-1 after 18 hrs by broth microdilution method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic.
AID67400In vitro antibacterial activity against Enterococcus faecalis strain ATCC 292121996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID67752Minimum inhibitory concentration against Enterococcus faecalis ATCC 145062004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID133421Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3HT12 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID244819Minimum inhibitory concentration against Streptococcus pneumoniae A95852005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID308918Antibacterial activity against Staphylococcus aureus ATCC 33592 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID208630Inhibitory activity against Streptococcus pneumoniae1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID133306Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3HM3 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206238In vitro antibacterial activity against Staphylococcus aures strain UC126731996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID112681In vivo antibacterial activity against Enterococcus faecalis strain UC 12379 administered perorally in mice1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID262230Antibacterial activity against Staphylococcus aureus ATCC 91442006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID206470The compound was evaluated for its anti-bacterial activity against methicillin susceptible Staphylococcus aureus1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID206840Minimum inhibitory concentration evaluated against Staphylococcus species resistant to oxacillin [66]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206451In vitro antibacterial activity against methicillin-susceptible Staphylococcus aureus (MSSA) C2214.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID23886Plasma clearance in Male Sprague-Dawley Rat (10 mg/kg iv)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID206055Inhibitory activity against methicillin-resistant Staphylococcus epidermidis (MRSE)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID262237Antibacterial activity against Streptococcus pyogenes ATCC 142892006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID206834In vitro anti-staphylococcal activity against Staphylococcus species resistant to oxacillin and ofloxacin[47]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID16465Calculated partition coefficient (clogP)1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.
AID66407In vitro anti-enterococcal activity against enterococci species susceptible to vancomycin [26]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID83641The compound was evaluated for its anti-bacterial activity against Haemophilus influenzae UC 300631998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID383562Antibacterial activity against multidrug-resistant Enterococcus faecalis ATCC 700802 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID30967Harmonic mean apparent terminal disposition half-life [t1/2beta (h)] in Male Sprague-Dawley Rat at dose 10 (mg/kg iv)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID226025Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3HM3 strain ) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1471364Binding affinity to Escherichia coli MRE600 50S ribosome after 10 mins by radioligand binding assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.
AID226023Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus pyogenes A1UC1 strain) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID383555Antibacterial activity against Bacillus pumilus ATCC 14884 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID30153Volume distribution in Male Sprague-Dawley Rat (10 mg/kg iv)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID28179Harmonic mean apparent terminal disposition half-life [t1/2beta (h)] in Male Sprague-Dawley Rat at dose 25 (mg/kg po); ND denotes not reported2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID41285Inhibitory activity against Bacteroides fragilis1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID206450In vitro antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) C6068.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID383559Antibacterial activity against Enterococcus faecalis ATCC 35550 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID41262In vitro antibacterial activity against Bacteroides fragilis strain ATCC 252851996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745373Inhibition of MAO-B in rat forebrain using [14C]PEA as substrate at 30 uM incubated for 20 mins prior to substrate addition measured after 10 mins by liquid scintillation counting analysis relative to control2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID262236Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 7008022006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID202107Inhibitory activity against Streptococcus pneumoniae UC99122000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID133303Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus pyogenes A1UC1 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308912Antibacterial activity against Bacillus subtilis ATCC 6633 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID66406In vitro anti-enterococcal activity against enterococci species resistant to vancomycin and teicoplanin [17]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID71095In vitro antibacterial activity against Escherichia coli strain ATCC 259221996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID262235Antibacterial activity against Enterococcus faecalis ATCC 145062006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID165190In vitro antibacterial activity against Pseudomonas aeruginosa strain ATCC 278531996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID29429Oral bioavailability in rat (Sprague-Dawley) (male) (dose 25 mg/kg p.o.)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID206993The compound was evaluated for its anti-bacterial activity against methicillin resistant Staphylococcus epidermidis1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID745378Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID205559Minimum inhibitory concentration against Staphylococcus aureus ATCC 141542004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID161942Minimum inhibitory concentration evaluated against pneumococci resistant to penicillin [29]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206613In vitro antibacterial activity against the methicillin-resistant Staphylococcus aureus 881999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.
AID206830In vitro anti-staphylococcal activity against Staphylococcus species [91]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206223In vitro antibacterial activity against Staphylococcus epidermis (S.e.2) C2235.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID745377Inhibition of human CYP1A2 assessed as ethoxyresorufin O-deethylation after 20 mins by fluorescence plate reader analysis2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID308926Antibacterial activity against Staphylococcus epidermidis ATCC 155 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID1553368Antibacterial activity against Staphylococcus aureus JC9213 by CLSI based broth dilution assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity.
AID161929In vitro anti-streptococcal activity against pneumococci resistant to penicillin [29]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID133304Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3AP9 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308917Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID209464In vitro antibacterial activity against Streptococcus pyogenes C6003 (S.p.2).1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID66560Minimum inhibitory concentration evaluated against enterococci species resistant to vancomycin and teicoplanin [17]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID103859Inhibitory activity against Moraxella catarrhalis UC306102000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID205561Minimum inhibitory concentration against Staphylococcus aureus ATCC 292132004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID319150Oral bioavailability in dog at 25 mg/kg2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID40326Minimum inhibitory concentration against Bacillus cereus MTCC 4302004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID308920Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206832In vitro anti-staphylococcal activity against Staphylococcus species resistant to ofloxacin [59]* expressed as geometric mean2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID132799compound was tested against Staphylococcus aureus UC9213 the vancomycin administered (sc) in mouse positive control expressed as ED50 values.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID745407Antibacterial activity against Staphylococcus aureus SR20549 clinical isolate assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID206056Inhibitory activity against methicillin-sensitive Staphylococcus epidermidis (MSSE)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID262233Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 7006992006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID67243In vitro antibacterial activity against Enterococcus faecalis C6291 (E.f.1).1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID226026Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3HM4 strain ) in murine2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID54143Inhibitory activity against Corynebacterium1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID208149Minimum inhibitory concentration Streptococcus pneumoniae UC99121998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID308919Antibacterial activity against multidrug resistant Enterococcus faecalis ATCC 700802 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID205560Minimum inhibitory concentration against Staphylococcus aureus ATCC 259232004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID206469The compound was evaluated for its anti-bacterial activity against methicillin resistant Staphylococcus aureus1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID745404Antibacterial activity against Enterococcus faecalis SR1004 clinical isolate assessed as growth inhibition by CLSI broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID308924Antibacterial activity against methicillin-resistant Streptococcus pyogenes ATCC 14289 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID262229Antibacterial activity against Staphylococcus aureus ATCC 259232006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID383568Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119 with G 2576T mutation by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID383570Antibacterial activity against multidrug-resistant Streptococcus pneumoniae ATCC 700904 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206222In vitro antibacterial activity against Staphylococcus epidermis (S.e.1) ATCC 1228.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID133291Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Enterococci faecium D3HT7 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID29723Tmax value in Male Sprague-Dawley Rat at dose 25 (mg/kg po) [tmax (h)]2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID319159Plasma concentration in human at 2000 mg, qid after 2 hrs2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID745375Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID262227Antibacterial activity against Staphylococcus epidermidis ATCC 1552006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID207510Minimum inhibitory concentration against Staphylococcus aureus UC66851998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID209463In vitro antibacterial activity against Streptococcus pyogenes ATCC 8668 (S.p.1).1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID383557Antibacterial activity against Streptococcus pyogenes ATCC 14289 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID308925Antibacterial activity against multidrug-resistant Streptococcus pneumoniae ATCC 700904 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID308923Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by broth microdilution method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206838Minimum inhibitory concentration evaluated against Staphylococcus species [91]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID201410Inhibitory activity against Methicillin-susceptible Staphylococcus aureus UC92132000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID206091Minimum inhibitory concentration evaluated against Streptococci species [38]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID745376Inhibition of human CYP2D6 assessed as dextromethorphan O-demethylation after 20 mins by LC/MS/MS analysis2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID745381Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 infected in JCL/ICR mouse systemic infection model assessed as mortality administered as po measured over 7 days2013European journal of medicinal chemistry, May, Volume: 63Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID28085Cmax value in Male Sprague-Dawley Rat at dose 10 (mg/kg iv)2003Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID67754Minimum inhibitory concentration against Enterococcus faecalis MTCC 4392004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Oxazolidinone: search for highly potent antibacterial.
AID262238Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 7009042006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID133290Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Enterococci faecalis D2HT6 strain in mice2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID319149Oral bioavailability in rat at 25 mg/kg2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID383560Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution technique2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID244813Minimum inhibitory concentration against Enterococcus faecium A248852005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID66559Minimum inhibitory concentration evaluated against enterococci species resistant to vancomycin [65]*2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's28 (50.91)18.2507
2000's20 (36.36)29.6817
2010's5 (9.09)24.3611
2020's2 (3.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.49 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.72%)5.53%
Reviews6 (10.34%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (87.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]